respiratory

Merck & Co plans to file cough drug gefapixant after phase 3 success

https://pharmaphorum.com/news/merck-co-plans-to-file-cough-drug-gefapixant-after-phase-3-success/

PureTech to develop drug to treat lung scarring in COVID-19 patients

https://pharmaphorum.com/news/puretech-to-develop-drug-to-treat-lung-scarring-in-covid-19-patients/

FREE TO ATTEND | Inhalation & Respiratory Drug Delivery Event: Virtual

https://pharmaphorum.com/partner-content/free-to-attend-inhalation-respiratory-drug-delivery-event-virtual/

FREE TO ATTEND | Formulation & Drug Delivery Event: Virtual

https://pharmaphorum.com/partner-content/free-to-attend-formulation-drug-delivery-event-virtual/

Verona says FDA backs plan to take COPD drug into phase 3

https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/

Novartis on point in EU for asthma triple as CHMP backs Enerzair

https://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/

Chiesi starts rare diseases division, ahead of potential Fabry disease filing

https://pharmaphorum.com/news/chiesi-starts-rare-diseases-division-as-fabry-treatment/

FDA clears emergency diagnostic as coronavirus fears mount

https://pharmaphorum.com/news/fda-clears-emergency-diagnostic-as-coronavirus-fears-mount/

FDA sets June date for latest review of Merck’s last-ditch antibiotic

https://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/

1 2 3 4 5 >»

Close in 10 seconds

Pharmaphorum.com

Search